News

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Texas Biomed taps new research leadership to help craft aggressive game plan

Joanne Turner has joined Texas Biomedical Research Institute as its new vice president of research. COURTESY ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
San Antonio’s Mission Pharmacal rolls out two new products
November 19, 2015

By Peggy O'Hare on November 19, 2015 at 3:27 PM

San Antonio pharmaceutical company Mission Pharmacal has introduced two new medications for adults suffering from coughs and colds.

The company has nationally launched HycofenixT Oral Solution, a prescription medication that relieves three cough and cold symptoms. The product features the first and only combination of hydrocodone, pseudoephedrine and guaifenesin approved by the U.S. Food and Drug Administration.

Hycofenix relieves coughing, loosens respiratory secretions for a more productive cough and clears nasal congestion.

Mission Pharmacal also launched another new product, FlowtussT Oral Solution, a prescription that relieves coughing and loosens respiratory secretions. The medication is an option for patients who are coughing, but do not need a nasal decongestant. It contains hydrocodone bitartrate and guaifenesin.

Both medications come in a black raspberry flavor and have been approved by the FDA for patients 18 years old and older.

To support customer needs related to Hycofenix and Flowtuss, we have nearly doubled the size of our sales team, said John McLaughlin, sales director of Mission Pharmacal’s primary care division. We are excited that the addition of these products in a new therapeutic class enables us to grow and better serve primary care providers and their patients.

Stay informed. Subscribe to BioMed SA news alerts.